Market Research Future
Blood Transfusion Diagnostics Market is expected to expand 8.2% CAGR during the forecast period 2019 to 2023
Blood Transfusion Diagnostics Market – Scenario “Blood transfusion laboratory is an essential part of providing healthcare services to the patients. Blood and blood products like RBC’s, WBC’s, platelets and others are transfused from one person to another. This requires screening tests which are vital before conducting blood transfusion. Strict regulation governing the use and transfer of blood, increasing awareness regarding blood transfusion and automation of blood banks drive the growth of this market. Risk involved in blood transfusion is transmission of infectious disease from one person to another without carrying out screening procedure. ”
Blood Transfusion Diagnostics market is expected to reach USD 2.45 billion by 2023 at a CAGR of 8.2% during the forecast period from 2017-2023. Request Free Sample https://www.marketresearchfuture.com/sample_request/1126
Copy
at
Key Players Market Research Future (MRFR) recognizes the following companies as the key players in Blood Transfusion Diagnostics Market: There are plenty of large and small market players which operate in this market all over the globe.
Major players in this market are: Ortho Clinical Diagnostics (U.S), Immucor (U.S), Beckman Coulter (U.S), Grifols (Spain), Thermo Fisher Scientific, Inc. (U.S.), Roche Diagnostics (Switzerland), bioMérieux (France), Bio-Rad Laboratories, Inc. (U.S.), Siemens Healthineers (Germany), Ortho Clinical Diagnostics, Inc. (U.S.), Becton, Dickinson and Company (U.S.), Novartis AG (Switzerland), Beckman Coulter, Inc. (U.S.), Diagast (France), Abbott Diagnostics (U.S), BAG healthcare (Germany), DiaSorin (Italy), Fujirebio (Belgium), Grifols (Spain), Quidel (U.S), Hologic/Gen-Probe (U.S), Biokit (Spain).